Outcomes of MIST for BPH: A Single-Institution Prospective Study

Status Not yet recruiting

Clinical Trial Summary

The investigators wish to perform a prospective study at the Men's Health Clinic in Winnipeg, Manitoba to accomplish two goals: 1) Prospectively describe 1 year outcomes for MIST therapies performed at the clinic 2) perform a head to head comparison of Rezum water vapor therapy vs the iTind device in respect to symptom score improvement, uroflow parameters and side effect profile.

Clinical Trial Description

This prospective study is to be conducted at the Men's Health Clinic in Winnipeg, Manitoba. All eligible patients who are to undergo Rezum or iTind procedure for BPH/LUTS between March 2024 and March 2025 are to be included in the study. Patient meeting inclusion criteria and exclusion criteria will be recruited to participate in this study. Inclusion criteria: patients > 18 years of age, undergoing Rezum or iTind treatment Exclusion criteria: ASA III or higher, active UTI within past week, age < 18 years of age, no informed consent Follow-up/data measurements will occur pre-procedure, immediately post procedure, 1 week, 6 weeks, and 3 months following procedure. At time of consultation pre-procedure, baseline symptom scores, uroflow parameters will be obtained. VAS pain score is to be obtained during procedure, immediately post procedure, and at time of catheter or device removal 1 week post procedure. Uroflow parameters and symptoms scores will be again measured at 6 weeks and 3 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06275256
Study type	Interventional
Source	University of Manitoba
Contact	Premal Patel, MD
Phone	204-221-4476
Email	ppatel5@hsc.mb.ca
Status	Not yet recruiting
Phase	Phase 3
Start date	March 2024
Completion date	March 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04807296` - Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP)	N/A
Recruiting	`NCT05574244` - Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction	N/A
Recruiting	`NCT04288427` - 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy	N/A
Not yet recruiting	`NCT04245566` - Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH	Phase 3
Withdrawn	`NCT01967251` - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction	Phase 2
Completed	`NCT02509975` - Safety and Efficacy of OCL 503 in Prostate Artery Embolization	N/A
Completed	`NCT03246880` - Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients	Phase 3
Completed	`NCT02206243` - Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
Completed	`NCT02283684` - GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT	Phase 4
Completed	`NCT01438775` - Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)	Phase 3
Completed	`NCT01454349` - Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)	Phase 1/Phase 2
Completed	`NCT01152190` - A Study in Benign Prostatic Hyperplasia	Phase 3
Completed	`NCT01139762` - A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms	Phase 3
Active, not recruiting	`NCT00400894` - Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma	N/A
Completed	`NCT00701779` - Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia	Phase 4
Unknown status	`NCT00381108` - Study of the Effects of Pomegranate Tablets on Enlarged Prostates	Phase 1
Completed	`NCT00224133` - The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months	Phase 3
Terminated	`NCT02962674` - To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH.	N/A
Active, not recruiting	`NCT05415748` - Deprescribing Tamsulosin in Older Men	Phase 4
Recruiting	`NCT04853914` - Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound.	N/A